Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical-trial disclosures, patent expiration timelines, or royalty obligations inside Pfizer’s massive SEC filings can feel like searching for a single molecule in a lab. Each 300-page Pfizer annual report 10-K simplified contains dozens of drug-pipeline tables, while every Pfizer quarterly earnings report 10-Q filing updates revenue by therapeutic area and COVID-19 vaccine demand. Add frequent 8-Ks announcing material study results and the picture grows increasingly complex for investors.
That’s where Stock Titan’s AI steps in. Our engine delivers real-time alerts and plain-English summaries the moment a new document hits EDGAR, turning Pfizer SEC filings explained simply into actionable insight. Need Pfizer insider trading Form 4 transactions? You’ll see executive stock trades within minutes, with context on trial milestones. Curious about Pfizer proxy statement executive compensation? Our AI highlights pay tied to oncology breakthroughs. Even Pfizer 8-K material events explained are broken down, so you understand why a Phase 3 success moves the stock.
Whether you’re comparing R&D spend across quarters, tracking Pfizer Form 4 insider transactions real-time, or performing Pfizer earnings report filing analysis, the platform ties each form to the questions professionals actually ask. Use the searchable dashboard to pinpoint:
- Segment revenue trends buried in 10-Qs
- Patent-cliff discussions inside the 10-K
- Pfizer executive stock transactions Form 4 around FDA decisions
Understanding Pfizer SEC documents with AI means no more manual page-turning—just concise insights on drug safety updates, collaboration economics, and global sales dynamics.
Core Natural Resources (NYSE: CNR) � Form 10-Q, quarter ended 30 Jun 2025
The first quarter after the all-stock merger with Arch Resources (closed 14 Jan 2025) shows a dramatic scale-up in size but near-term earnings pressure.
- Revenue: Q2 25 $1.10 bn (+125% YoY); 1H 25 $2.12 bn (+104%).
- Net loss: Q2 25 $(36.6) m vs +$58.1 m; 1H 25 $(105.8) m vs +$160.0 m. Losses reflect higher cost of sales, $291 m DD&A and ~$38 m merger & integration expenses.
- EPS: basic and diluted �$0.70 (Q2) and �$2.06 (1H).
- Cash flow (1H): Ops +$110.5 m; Capex �$154.0 m; Share buybacks �$183.2 m; Dividends $0.20/sh.
- Balance sheet post-merger: Assets $6.21 bn (up from $2.88 bn at FY-24); Equity $3.77 bn. Cash & equivalents $413 m; Net debt ~$(42) m (cash exceeds debt); 1.50× first-lien leverage covenant headroom vs 0.13× actual.
- Segment mix Q2: Coal revenue $1.09 bn (45% domestic, 55% export) split among Power Generation 44%, Industrial 25%, Metallurgical 31%. Terminal & Other revenue $9 m.
- Purchase price allocation: $2.58 bn consideration; preliminary $1.4 bn PP&E fair-value step-up; identifiable intangibles $84 m.
Outlook: Management has yet to provide updated synergy targets; integration costs and higher DD&A will pressure FY-25 profit, but liquidity is strong and leverage low. Investors will watch for margin recovery, cost synergies and export pricing.
Pfizer Inc. (PFE) � Form 4 insider filing shows Chairman & CEO Albert Bourla acquired a de minimis 26 phantom stock units on 31-Jul-2025 through the company’s Non-Funded Deferred Compensation and Supplemental Savings Plan (SSP).
� Transaction code: A (acquisition).
� Unit price: $23.29.
� Total value: � $606.
� Post-transaction holdings: 731,620 phantom stock units, held directly (D).
Phantom units are cash-settled and do not alter the public share count; the participant may transfer them into another investment option at any time. No common stock transactions were reported in Table I.
Materiality: The addition represents less than 0.01 % of Bourla’s existing derivative position and has no discernible impact on Pfizer’s capital structure or governance.
Bank of Montreal is offering US$435,000 of Senior Medium-Term Digital Return Notes, Series K, linked to FedEx Corporation (FDX) common stock. The three-year notes (Pricing Date : 30 Jun 2025; Maturity : 03 Jul 2028) pay a single 26.00% digital return if FDX’s closing price on the Valuation Date is at least equal to the Initial Level of $227.31. Should the Final Level fall below the Initial Level, investors receive only principal, resulting in a 0% return. There is no participation above 26% and the notes bear no periodic interest.
Key economic terms include: Digital Barrier = 100% of Initial Level; minimum denomination = $1,000; CUSIP 06376EHA3. The notes are unsecured, unsubordinated obligations of Bank of Montreal and are subject to issuer credit risk. They will not be listed, and any liquidity will rely on BMO Capital Markets Corp. acting as a market-maker. Issue price equals 100%, with a 0.75% selling commission; the estimated initial value is $986.68 per $1,000, reflecting embedded dealer compensation and hedging costs.
The filing highlights material risks: upside capped at 26%, potential under-performance versus conventional bonds, lack of dividends, secondary-market uncertainty, conflicts of interest in the calculation agent role, and complex U.S. tax treatment as contingent payment debt instruments. The product may appeal to investors seeking principal preservation plus a defined payoff contingent on non-negative FDX performance, but it sacrifices income and exposes holders to both FedEx share volatility and Bank of Montreal’s credit profile.
Bank of Montreal is offering US$435,000 of Senior Medium-Term Digital Return Notes, Series K, linked to FedEx Corporation (FDX) common stock. The three-year notes (Pricing Date : 30 Jun 2025; Maturity : 03 Jul 2028) pay a single 26.00% digital return if FDX’s closing price on the Valuation Date is at least equal to the Initial Level of $227.31. Should the Final Level fall below the Initial Level, investors receive only principal, resulting in a 0% return. There is no participation above 26% and the notes bear no periodic interest.
Key economic terms include: Digital Barrier = 100% of Initial Level; minimum denomination = $1,000; CUSIP 06376EHA3. The notes are unsecured, unsubordinated obligations of Bank of Montreal and are subject to issuer credit risk. They will not be listed, and any liquidity will rely on BMO Capital Markets Corp. acting as a market-maker. Issue price equals 100%, with a 0.75% selling commission; the estimated initial value is $986.68 per $1,000, reflecting embedded dealer compensation and hedging costs.
The filing highlights material risks: upside capped at 26%, potential under-performance versus conventional bonds, lack of dividends, secondary-market uncertainty, conflicts of interest in the calculation agent role, and complex U.S. tax treatment as contingent payment debt instruments. The product may appeal to investors seeking principal preservation plus a defined payoff contingent on non-negative FDX performance, but it sacrifices income and exposes holders to both FedEx share volatility and Bank of Montreal’s credit profile.
Bank of Montreal is offering US$435,000 of Senior Medium-Term Digital Return Notes, Series K, linked to FedEx Corporation (FDX) common stock. The three-year notes (Pricing Date : 30 Jun 2025; Maturity : 03 Jul 2028) pay a single 26.00% digital return if FDX’s closing price on the Valuation Date is at least equal to the Initial Level of $227.31. Should the Final Level fall below the Initial Level, investors receive only principal, resulting in a 0% return. There is no participation above 26% and the notes bear no periodic interest.
Key economic terms include: Digital Barrier = 100% of Initial Level; minimum denomination = $1,000; CUSIP 06376EHA3. The notes are unsecured, unsubordinated obligations of Bank of Montreal and are subject to issuer credit risk. They will not be listed, and any liquidity will rely on BMO Capital Markets Corp. acting as a market-maker. Issue price equals 100%, with a 0.75% selling commission; the estimated initial value is $986.68 per $1,000, reflecting embedded dealer compensation and hedging costs.
The filing highlights material risks: upside capped at 26%, potential under-performance versus conventional bonds, lack of dividends, secondary-market uncertainty, conflicts of interest in the calculation agent role, and complex U.S. tax treatment as contingent payment debt instruments. The product may appeal to investors seeking principal preservation plus a defined payoff contingent on non-negative FDX performance, but it sacrifices income and exposes holders to both FedEx share volatility and Bank of Montreal’s credit profile.
Bank of Montreal is offering US$435,000 of Senior Medium-Term Digital Return Notes, Series K, linked to FedEx Corporation (FDX) common stock. The three-year notes (Pricing Date : 30 Jun 2025; Maturity : 03 Jul 2028) pay a single 26.00% digital return if FDX’s closing price on the Valuation Date is at least equal to the Initial Level of $227.31. Should the Final Level fall below the Initial Level, investors receive only principal, resulting in a 0% return. There is no participation above 26% and the notes bear no periodic interest.
Key economic terms include: Digital Barrier = 100% of Initial Level; minimum denomination = $1,000; CUSIP 06376EHA3. The notes are unsecured, unsubordinated obligations of Bank of Montreal and are subject to issuer credit risk. They will not be listed, and any liquidity will rely on BMO Capital Markets Corp. acting as a market-maker. Issue price equals 100%, with a 0.75% selling commission; the estimated initial value is $986.68 per $1,000, reflecting embedded dealer compensation and hedging costs.
The filing highlights material risks: upside capped at 26%, potential under-performance versus conventional bonds, lack of dividends, secondary-market uncertainty, conflicts of interest in the calculation agent role, and complex U.S. tax treatment as contingent payment debt instruments. The product may appeal to investors seeking principal preservation plus a defined payoff contingent on non-negative FDX performance, but it sacrifices income and exposes holders to both FedEx share volatility and Bank of Montreal’s credit profile.
Insider activity overview: On 07/02/2025 ZimVie Inc. (ZIMV) filed a Form 4 indicating that independent director Richard Kuntz acquired 1,340.909 Deferred Share Units (DSUs) on 06/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors.
� Economic terms: Each DSU is economically equivalent to one share of ZimVie common stock (1-for-1 conversion). The filing lists a reference price of $9.35 but the footnote clarifies the award settles in cash once board service ends.
� Post-transaction holdings: Kuntz now beneficially owns 12,410.656 DSUs; no open-market purchases or sales of common shares were reported. Ownership remains direct, and no derivative instruments with an expiration schedule were created.
� Materiality assessment: The transaction represents routine non-cash director compensation and does not alter ZimVie’s capital structure or cash flows. Therefore, it is considered neutral for near-term valuation but it modestly aligns director incentives with shareholder performance over time.
Form 4 snapshot: On 06/30/2025, Pfizer Inc. (PFE) Chairman & CEO Albert Bourla was credited with 25 Phantom Stock Units at a reference price of $24.24 under the company’s Non-funded Deferred Compensation and Supplemental Savings Plan (SSP). Each unit mirrors one share of Pfizer common stock but will be settled in cash after the executive’s separation from service and can be reallocated to other plan investments at any time.
After this routine accrual, Bourla’s total phantom-unit balance stands at 718,220 units. The filing discloses no open-market purchases or sales of Pfizer common stock, and there is no change to his direct share ownership.
Given the immaterial size of the grant (25 units) and its deferred-compensation nature, the transaction is considered administrative and non-market-moving. Investors should view the disclosure as a standard update required by Section 16 rather than a signal of management’s near-term view on Pfizer’s share price.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
What is Pfizer's core business?
How does Pfizer generate revenue?
Which therapeutic areas does Pfizer focus on?
How is Pfizer organized internationally?
What role does research and development play at Pfizer?
How does Pfizer differentiate itself in the competitive pharmaceutical market?
What are some of the key factors behind Pfizer's operational success?
How does Pfizer impact global healthcare?
